
## Natasha J Caplen

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/2395308/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Unique microRNA molecular profiles in lung cancer diagnosis and prognosis. Cancer Cell, 2006, 9, 189-198.	7.7	2,870
2	Specific inhibition of gene expression by small double-stranded RNAs in invertebrate and vertebrate systems. Proceedings of the National Academy of Sciences of the United States of America, 2001, 98, 9742-9747.	3.3	982
3	Liposome-mediated CFTR gene transfer to the nasal epithelium of patients with cystic fibrosis. Nature Medicine, 1995, 1, 39-46.	15.2	736
4	Short interfering RNAs can induce unexpected and divergent changes in the levels of untargeted proteins in mammalian cells. Proceedings of the National Academy of Sciences of the United States of America, 2004, 101, 1892-1897.	3.3	543
5	Non–invasive liposome–mediated gene delivery can correct the ion transport defect in cystic fibrosis mutant mice. Nature Genetics, 1993, 5, 135-142.	9.4	425
6	dsRNA-mediated gene silencing in cultured Drosophila cells: a tissue culture model for the analysis of RNA interference. Gene, 2000, 252, 95-105.	1.0	229
7	RNAi Microarray Analysis in Cultured Mammalian Cells. Genome Research, 2003, 13, 2341-2347.	2.4	173
8	p53-dependent Induction of PVT1 and miR-1204. Journal of Biological Chemistry, 2012, 287, 2509-2519.	1.6	165
9	Selective Toxicity of NSC73306 in MDR1-Positive Cells as a New Strategy to Circumvent Multidrug Resistance in Cancer. Cancer Research, 2006, 66, 4808-4815.	0.4	162
10	The Identification of MicroRNAs in a Genomically Unstable Region of Human Chromosome 8q24. Molecular Cancer Research, 2008, 6, 212-221.	1.5	159
11	Defining and Assaying RNAi in Mammalian Cells. Molecular Cell, 2005, 17, 1-10.	4.5	136
12	The 8q24 Gene Desert: An Oasis of Non-Coding Transcriptional Activity. Frontiers in Genetics, 2012, 3, 69.	1.1	127
13	Applications of RNA Interference in Mammalian Systems. Annual Review of Genomics and Human Genetics, 2007, 8, 81-108.	2.5	124
14	Kinase-Independent Functions for Itk in TCR-Induced Regulation of Vav and the Actin Cytoskeleton. Journal of Immunology, 2005, 174, 1385-1392.	0.4	121
15	Gene Therapy Progress and Prospects. Downregulating gene expression: the impact of RNA interference. Gene Therapy, 2004, 11, 1241-1248.	2.3	119
16	Implication of Checkpoint Kinase-dependent Up-regulation of Ribonucleotide Reductase R2 in DNA Damage Response. Journal of Biological Chemistry, 2009, 284, 18085-18095.	1.6	116
17	Single-step doxorubicin-selected cancer cells overexpress the ABCG2 drug transporter through epigenetic changes. British Journal of Cancer, 2008, 98, 1515-1524.	2.9	106
18	Identification of the receptor tyrosine kinase AXL in breast cancer as a target for the human miR-34a microRNA. Breast Cancer Research and Treatment, 2011, 130, 663-679.	1.1	101

#	Article	IF	CITATIONS
19	Rescue of polyglutamine-mediated cytotoxicity by double-stranded RNA-mediated RNA interference. Human Molecular Genetics, 2002, 11, 175-184.	1.4	100
20	Pvt1-encoded microRNAs in oncogenesis. Retrovirology, 2008, 5, 4.	0.9	100
21	Asparagine synthetase as a causal, predictive biomarker for l-asparaginase activity in ovarian cancer cells. Molecular Cancer Therapeutics, 2006, 5, 2613-2623.	1.9	97
22	MAP kinase and autophagy pathways cooperate to maintain RAS mutant cancer cell survival. Proceedings of the National Academy of Sciences of the United States of America, 2019, 116, 4508-4517.	3.3	97
23	Cellular Inhibition of Checkpoint Kinase 2 (Chk2) and Potentiation of Camptothecins and Radiation by the Novel Chk2 Inhibitor PV1019 [7-Nitro-1 <i>H</i> -indole-2-carboxylic acid {4-[1-(guanidinohydrazone)-ethyl]-phenyl}-amide]. Journal of Pharmacology and Experimental Therapeutics. 2009. 331. 816-826.	1.3	90
24	Identification of WEE1 as a potential molecular target in cancer cells by RNAi screening of the human tyrosine kinome. Breast Cancer Research and Treatment, 2010, 122, 347-357.	1.1	77
25	Inhibition of Viral Gene Expression and Replication in Mosquito Cells by dsRNA-Triggered RNA Interference. Molecular Therapy, 2002, 6, 243-251.	3.7	76
26	Short Interfering RNA (siRNA)-Mediated RNA Interference (RNAi) in Human Cells. Annals of the New York Academy of Sciences, 2003, 1002, 56-62.	1.8	75
27	MicroRNAs and genomic instability. Seminars in Cancer Biology, 2007, 17, 65-73.	4.3	74
28	RNAi as a gene therapy approach. Expert Opinion on Biological Therapy, 2003, 3, 575-586.	1.4	68
29	Genetic Amplification of the NOTCH Modulator LNX2 Upregulates the WNT/β-Catenin Pathway in Colorectal Cancer. Cancer Research, 2013, 73, 2003-2013.	0.4	68
30	Inefficient cationic lipid-mediated siRNA and antisense oligonucleotide transfer to airway epithelial cells in vivo. Respiratory Research, 2006, 7, 26.	1.4	59
31	Functional Genomic Screening Reveals Splicing of the EWS-FL11 Fusion Transcript as a Vulnerability in Ewing Sarcoma. Cell Reports, 2016, 14, 598-610.	2.9	53
32	Inhibition of polo-like kinase 1 in glioblastoma multiforme induces mitotic catastrophe and enhances radiosensitisation. European Journal of Cancer, 2013, 49, 3020-3028.	1.3	51
33	Targeting <i>MPS1</i> Enhances Radiosensitization of Human Glioblastoma by Modulating DNA Repair Proteins. Molecular Cancer Research, 2015, 13, 852-862.	1.5	50
34	Adeno-retroviral chimeric viruses as in vivo transducing agents. Gene Therapy, 1999, 6, 454-459.	2.3	43
35	Systems-wide RNAi analysis of CASP8AP2/FLASH shows transcriptional deregulation of the replication-dependent histone genes and extensive effects on the transcriptome of colorectal cancer cells. Molecular Cancer, 2012, 11, 1.	7.9	42
36	A genomic strategy for the functional validation of colorectal cancer genes identifies potential therapeutic targets. International Journal of Cancer, 2011, 128, 1069-1079.	2.3	41

#	Article	IF	CITATIONS
37	EWSâ€FLI1 reprograms the metabolism of Ewing sarcoma cells via positive regulation of glutamine import and serineâ€glycine biosynthesis. Molecular Carcinogenesis, 2018, 57, 1342-1357.	1.3	40
38	SpliceCenter: A suite of web-based bioinformatic applications for evaluating the impact of alternative splicing on RT-PCR, RNAi, microarray, and peptide-based studies. BMC Bioinformatics, 2008, 9, 313.	1.2	36
39	RNAi Screening Identifies TAK1 as a Potential Target for the Enhanced Efficacy of Topoisomerase Inhibitors. Current Cancer Drug Targets, 2011, 11, 976-986.	0.8	36
40	Efficient Delivery of RNA Interference Effectors via in vitro-Packaged SV40 Pseudovirions. Human Gene Therapy, 2005, 16, 1110-1115.	1.4	35
41	HNRNPH1-dependent splicing of a fusion oncogene reveals a targetable RNA G-quadruplex interaction. Rna, 2019, 25, 1731-1750.	1.6	34
42	Identification and validation of genes with expression patterns inverse to multiple metastasis suppressor genes in breast cancer cell lines. Clinical and Experimental Metastasis, 2014, 31, 771-786.	1.7	33
43	Localization and up-regulation of Mucin (MUC2) gene expression in human nasal biopsies of patients with cystic fibrosis. , 1997, 181, 305-310.		30
44	Adenovirus Vectors as Transcomplementing Templates for the Production of Replication Defective Retroviral Vectors. Biochemical and Biophysical Research Communications, 1998, 246, 912-919.	1.0	29
45	A new approach to the inhibition of gene expression. Trends in Biotechnology, 2002, 20, 49-51.	4.9	27
46	Cross-species genomic and functional analyses identify a combination therapy using a CHK1 inhibitor and a ribonucleotide reductase inhibitor to treat triple-negative breast cancer. Breast Cancer Research, 2012, 14, R109.	2.2	24
47	BRD4 facilitates DNA damage response and represses CBX5/Heterochromatin protein 1 (HP1). Oncotarget, 2017, 8, 51402-51415.	0.8	24
48	Loss-of-function RNAi screens in breast cancer cells identify AURKB, PLK1, PIK3R1, MAPK12, PRKD2, and PTK6 as sensitizing targets of rapamycin activity. Cancer Letters, 2014, 354, 336-347.	3.2	22
49	Identification of novel molecular regulators of tumor necrosis factor-related apoptosis-inducing ligand (TRAIL)-induced apoptosis in breast cancer cells by RNAi screening. Breast Cancer Research, 2014, 16, R41.	2.2	22
50	Fusion transcripts: Unexploited vulnerabilities in cancer?. Wiley Interdisciplinary Reviews RNA, 2020, 11, e1562.	3.2	21
51	Selective targeting of KRAS-Mutant cells by miR-126 through repression of multiple genes essential for the survival of KRAS-Mutant cells. Oncotarget, 2014, 5, 7635-7650.	0.8	21
52	Mismatched siRNAs downregulate mRNAs as a function of target site location. FEBS Letters, 2006, 580, 3694-3698.	1.3	20
53	In situ generation of pseudotyped retroviral progeny by adenovirus-mediated transduction of tumor cells enhances the killing effect of HSV-tk suicide gene therapyin vitro andin vivo. Journal of Gene Medicine, 2004, 6, 288-299.	1.4	19
54	Multiplexing siRNAs to compress RNAi-based screen size in human cells. Nucleic Acids Research, 2007, 35, e57-e57.	6.5	19

#	Article	IF	CITATIONS
55	Alleleâ€specific silencing of the dominant disease allele in sialuria by RNA interference. FASEB Journal, 2008, 22, 3846-3852.	0.2	15
56	HNRNPH1 destabilizes the G-quadruplex structures formed by G-rich RNA sequences that regulate the alternative splicing of an oncogenic fusion transcript. Nucleic Acids Research, 2022, 50, 6474-6496.	6.5	14
57	New treatments for cystic fibrosis. British Medical Bulletin, 1992, 48, 785-804.	2.7	9
58	Genomic instability and mouse microRNAs. Toxicology Mechanisms and Methods, 2011, 21, 325-333.	1.3	9
59	RNAi quashes polyQ. Nature Medicine, 2004, 10, 775-776.	15.2	7
60	Identification of therapeutic targets applicable to clinical strategies in ovarian cancer. BMC Cancer, 2016, 16, 678.	1.1	7
61	Cancer biology functional genomics: From small RNAs to big dreams. Molecular Carcinogenesis, 2020, 59, 1343-1361.	1.3	6
62	Comprehensive profiling of mRNA splicing indicates that GC content signals altered cassette exon inclusion in Ewing sarcoma. NAR Cancer, 2022, 4, zcab052.	1.6	5
63	Cystic fibrosis gene therapy trials and tribulations. Trends in Molecular Medicine, 2001, 7, 488.	3.5	4
64	Gene silencing through RNA interference: Potential for therapeutics and functional genomics. International Journal of Peptide Research and Therapeutics, 2003, 10, 361-372.	0.9	3
65	RNAi as a gene therapy approach. , 0, .		3
66	Cystic Fibrosis: Gene Therapy Approaches. , 0, , 207-226.		2
67	MIROME ARCHITECTURE AND GENOMIC INSTABILITY. , 0, , 133-147.		1
68	Abstract 1952: The rapid generation of mouse B cell lymphomas by lentiviral mediated overexpression of miR-1204 from a genetically unstable region of human 8q24. , 2010, , .		1
69	Abstract 15: gp78 is a negative regulator of TRAIL-induced apoptosis in breast cancer cells. Cancer Research, 2015, 75, 15-15.	0.4	1
70	Gene silencing through RNA interference: Potential for therapeutics and functional genomics. International Journal of Peptide Research and Therapeutics, 2003, 10, 361-372.	0.1	0
71	Gene silencing through RNA interference: Potential for therapeutics and functional genomics. International Journal of Peptide Research and Therapeutics, 2005, 10, 361-372.	0.9	0

Gene Silencing by RNA Interference and the Role of Small Interfering RNAs. , 2004, , .

#	Article	IF	CITATIONS
73	Abstract A117: Chk1â€dependent upâ€regulation of ribonucleotide reductase R2 in response to camptothecinâ€induced DNA damage. , 2009, , .		0
74	Abstract A120: Cellular inhibition of Chk2 kinase and potentiation of camptothecins and radiation by the novel Chk2 inhibitor PV1019. , 2009, , .		0
75	Abstract 2098: The receptor tyrosine kinase AXL is a target for the human miR-34a microRNA. , 2010, , .		0
76	Abstract LB-74: A high-throughput RNAi sensitization screen of rapamycin identifies targets for rational drug combination strategies. , 2010, , .		0
77	Abstract 247: A functional genomics and a systems biology approach identify POMP as a potential therapeutic target for colorectal cancer. , 2010, , .		0
78	Abstract 2041: Large-scale RNAi screening identifies PCTK3/CDK18 as a putative cancer-related molecular target. , 2011, , .		0
79	Abstract 4106: A functional genomic approach to identify novel molecular regulators of the TRAIL pathway in breast cancer. , 2011, , .		0
80	Abstract 1181: Expression studies from the PVT1 region of 8q24. , 2011, , .		0
81	Abstract 96: From genome-wide association studies (GWAS) to functional genomics of prostate cancer: exploring the role of candidate transcripts through RNAi-based analysis. , 2012, , .		Ο
82	Abstract 267: Large-scale RNAi screening of human kinome identifies putative breast cancer related molecular targets. , 2012, , .		0
83	Abstract 199: Noncoding RNAs of the 8q24 locus. , 2012, , .		0
84	Identification of TNK2 as a critical kinase in rhabdomyosarcoma through a loss of function shRNA screen Journal of Clinical Oncology, 2012, 30, 9511-9511.	0.8	0
85	Abstract 4408: A functional genomics approach for identification of sirolimus sensitizer genes regulated by HDAC inhibitors , 2013, , .		0
86	Integrated analysis of RNAi screens in pediatric rhabdomyosarcoma Journal of Clinical Oncology, 2013, 31, 10040-10040.	0.8	0
87	Abstract B25: An unbiased functional screen identifies kinases essential to ovarian cancer cell survival. , 2013, , .		0
88	Abstract C222: The identification of kinase targets in Ewing sarcoma cell lines using RNAi and high-throughput investigational agents screens , 2013, , .		0
89	Lipid Gene Transfer and Clinical Gene Therapy. , 1998, , 205-217.		0
90	Lipid Gene Trasfer, a Story of Simplicity and Complexity. , 1998, , 185-194.		0

6

#	Article	IF	CITATIONS
91	Abstract LB-87: Analysis of JAZF1 loss-of-function reveals its role in regulation of genes relevant for prostate cancer. , 2014, , .		0
92	Abstract 5124: Identification and characterization of novel regulators of TRAIL-induced apoptosis in breast cancer cells. , 2014, , .		0
93	Abstract 520: Functional genomic screens identify microRNA regulators of the oncogenic fusion transcription factor EWS-FLI1. , 2014, , .		0
94	Abstract 479: Inhibition of the splicing of the EWS-FLI1 fusion transcript reverses EWS-FLI1 driven oncogenic expression in Ewing sarcoma. , 2015, , .		0
95	Abstract 2008: Ewing sarcoma cells harboring a translocation that retains EWSR1 exon 8 require HNRNPH1 to express the in-frame oncogenic fusion transcript EWS-FL11. , 2016, , .		0
96	Abstract 5471: EWS-FLI1 reprograms the metabolism of Ewing sarcoma cells via positive regulation of glutamine import and serine-glycine biosynthesis. , 2018, , .		0
97	Abstract 1632: Suppression of EWS-FLI1 transcription using a combination therapy of mithramycin and cyclin-dependent kinase 9 inhibition. , 2018, , .		0
98	Abstract 4494: HNRNPH1-dependent splicing of a fusion oncogene reveals a targetable RNA G-quadruplex interaction. , 2019, , .		0
99	Gene Silencing through RNA Interference. , 2006, , 252-264.		0